SpikImm
Paris, France· Est. 2017
Our lead asset, SPK004, addresses a severe unmet medical need in kidney transplant recipients. Due to the immunosuppressive treatments required to prevent graft rejection, these patients are highly susceptible to the reactivation of a dormant virus known as BK virus (BKV).
Private Company
Total funding raised: $33M
About
Our lead asset, SPK004, addresses a severe unmet medical need in kidney transplant recipients. Due to the immunosuppressive treatments required to prevent graft rejection, these patients are highly susceptible to the reactivation of a dormant virus known as BK virus (BKV).
AntibodiesBiologics
Funding History
2Total raised:$33M
Series A$25MApr 15, 2022
Seed$8MOct 15, 2020